证券代码：300677 证券简称：英科医疗 公告编号：2025-145 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 英科医疗科技股份有限公司 关于 2022 年限制性股票激励计划第三期 解除限售股份上市流通提示性公告 1、本次符合解除限售条件的激励对象共计 535 人，实际解除限 售股份数量为 1,052,520 股，占公司当前股本总额的 0.1607%。 2、本次解除限售的限制性股票解除限售日即上市流通日为 2025 年 10 月 29 日。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 20 日召开了第四届董事会第十一次会议，审议通过了《关于公司 2022 年限制性股票激励计划第三期解除限售条件成就的议案》，并 根据公司 2022 年第二次临时股东大会的授权依照的相关规定，办理 了解除限售股份上市流通的相关事宜，现就有关事项公告如下： 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 1、2022 年 6 月 9 日，公司召开第三届董事会第三次会议及第三 届监事会第三次会议，审议通过了《关于公司<2022 年 ...

关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：300677 证券简称：英科医疗 公告编号：2025-144 英科医疗科技股份有限公司 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担 ...

证券之星消息，截至2025年10月22日收盘，英科医疗(300677)报收于40.71元，下跌2.28%，换手率 3.51%，成交量16.33万手，成交额6.7亿元。 10月22日的资金流向数据方面，主力资金净流出6462.15万元，占总成交额9.65%，游资资金净流入 1985.44万元，占总成交额2.96%，散户资金净流入4476.71万元，占总成交额6.68%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-22 | 40.71 | -2.28% | -6462.15万 | -9.65% | 1985.44万 | 2.96% | 4476.71万 | - 6.68% | | 2025-10-21 | 41.66 | -0.83% | -1.05亿 | -12.35% | 5890.94万 | 6.96% | 4565.76万 | 5.39% | | 2025-10-20 ...

Core Insights - As of October 21, a total of 66 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Fanwei Network, which has seen net buying for 10 trading days [1] - Other notable stocks with significant consecutive net inflows include Mindray Medical, Yingke Medical, Shenjian Co., Xingqi Eye Medicine, Maixinlin, Deep Technology, Diweier, and Haide Co. [1]

（原标题：我国胰岛素口服递送取得新突破；脑机接口企业使失明患者恢复视力） 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 国家药监局：加大医疗器械研发创新支持力度 加快创新产品上市步伐 10月21日，由国家药监局南方医药经济研究所主办的"2025医疗器械经济信息发布会"在合肥召开。会议 指出，国家药监局将进一步完善法律标准体系，加大研发创新支持力度，提高审评审批质效，全方位筑 牢医疗器械高水平安全底线，加快创新产品上市步伐，促进医疗器械产业创新高质量发展。 10月21日，国药股份(600511.SH)公告称，国药股份发布2025年第三季度报告，第三季度公司实现营业 收入137.47亿元，同比增长3.58%；归属于上市公司股东的净利润为5.44亿元，同比增长13.10%。 资本市场 药械审批 圣因生物靶向C3 siRNA药物SGB-9768获FDA孤儿药资格认定 10月21日，圣因生物（SanegeneBio）宣布，其自主研发的靶向补体C3的siRNA药物SGB-9768注射液近 日获得美国食品药品监督管理局（FDA）孤儿药资格认定（Orphan Drug ...

Core Viewpoint - The company, Yingke Medical, is actively engaging in investment and stock incentive plans, indicating a strategic focus on growth and shareholder value enhancement through various financial maneuvers [1][2][4]. Trading Information Summary - On October 21, 2025, Yingke Medical's stock closed at 41.66 yuan, down 0.83%, with a turnover rate of 4.35%, a trading volume of 202,400 lots, and a transaction amount of 847 million yuan [1]. - On the same day, the net outflow of main funds was 105 million yuan, while speculative funds and retail investors saw net inflows of approximately 58.91 million yuan and 45.66 million yuan, respectively [1][4]. Company Announcement Summary - The fourth board meeting of Yingke Medical on October 20, 2025, approved several resolutions, including a plan for its wholly-owned subsidiary to invest 70 million USD in Warburg Pincus Global Growth 15, L.P., which targets a fundraising goal of at least 17 billion USD across various sectors [1]. - The company agreed to lift the restrictions on the third phase of the 2022 restricted stock incentive plan, involving 540 participants and a total of 1,052,520 shares, which accounts for 0.1607% of the current total share capital [2]. - Due to changes in equity distribution and other factors, the company plans to adjust its registered capital from 641.700369 million yuan to 654.383263 million yuan, with corresponding amendments to its articles of association [2][4]. - The company intends to repurchase and cancel a total of 410,480 shares from the restricted stock incentive plans of 2022 and 2025, with adjusted repurchase prices set at 10.91 yuan and 11.25 yuan per share, respectively [2][4]. Upcoming Events Summary - Yingke Medical will hold its sixth extraordinary general meeting on November 5, 2025, to discuss the adjustment of the restricted stock repurchase price and the cancellation of certain restricted stocks, requiring a two-thirds majority vote from attending shareholders [3].

Core Insights - Company has been awarded the "National Sales Leader in Disposable Gloves" and "National Sales Leader in Disposable Nitrile Gloves" by a renowned market research firm, confirming its leading position in the domestic disposable glove market [1][5]. Group 1: Market Position - The market position statements were based on sales volume data from January 1 to December 31, 2024, across all channels in mainland China, excluding Hong Kong, Macau, and Taiwan [5]. - The recognition of being the top seller in both categories reflects the company's deep investments in technology, production, and marketing [5]. Group 2: Production and R&D - The company has over 16 years of R&D and production experience, with a strong focus on building a comprehensive R&D innovation system [5]. - The company and its subsidiaries hold a total of 300 patents, showcasing its commitment to innovation [5]. Group 3: Production Capacity - The company operates six major production bases in China, ensuring optimized capacity and efficiency [6]. - The annual production capacity in the core disposable glove business reaches 87 billion units [6]. Group 4: Marketing and Sales Performance - The company has expanded its retail channels, establishing a strong online presence across platforms like Tmall, JD.com, Douyin, and Pinduoduo, as well as offline partnerships with major supermarkets [8]. - In 2025, the company reported a revenue of 4.913 billion yuan, with a year-on-year net profit growth of 21.02%, and domestic sales revenue increased by approximately 35% [8].

Core Insights - As of October 20, a total of 79 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] Group 1: Stocks with Longest Continuous Net Inflows - The stocks with the longest continuous net inflows are Yongmaotai, Kede CNC, and Fanwei Network, each having recorded net inflows for nine consecutive trading days [1] - Other notable stocks with significant net inflows include Mindray Medical, BOE Technology Group, Xingqi Eye Medicine, Maixinlin, Dongfang Electronics, Cangzhou Mingzhu, Zhongke Software, and Yingke Medical [1]

NO.1 复宏汉霖ADC 药物HLX43获FDA孤儿药资格认定 10月20日，复宏汉霖宣布，公司创新型程序性死亡-配体1（PD-L1）抗体偶联药物（ADC）注射用 HLX43已获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，用于胸腺上皮肿瘤（TETs） 的治疗。 获得FDA孤儿药资格认定的药物将享有包括但不限于：临床试验费用的税收抵免；免除新药申请费；获 批后七年的市场独占权等一系列政策支持，以加速其开发进程，早日惠及患者。 点评：此次获FDA授予孤儿药资格认定是HLX43全球开发进程中的又一重要里程碑，意味着该产品在 胸腺上皮肿瘤领域的突破性治疗潜力获得国际权威机构认可，有望进一步缩短HLX43的全球开发周 期，加速填补该疾病ADC治疗的空白。 NO.2 泽璟制药：盐酸吉卡昔替尼片治疗强直性脊柱炎III期临床试验达主要疗效终点 10月20日，英科医疗公告称，公司全资子公司英科医疗国际拟与Warburg PincusGlobal Growth 15 GP, L.P.（以下简称华平投资）签署认购协议以自有资金参与投资Warburg Pincus Global Growth15, L.P.（以 下简称合 ...

Core Viewpoint - The company, Yingke Medical, has reported a decline in stock price and significant changes in its capital structure, alongside key developments in its incentive plans and investment activities [1][2][3]. Trading Information Summary - On October 20, 2025, Yingke Medical's stock closed at 42.01 yuan, down 2.21%, with a turnover rate of 6.49% and a trading volume of 301,700 hands, resulting in a transaction amount of 1.261 billion yuan [1]. - The net outflow of main funds was 52.69 million yuan, while retail investors saw a net inflow of 39.54 million yuan [1][4]. Shareholder and Capital Changes - The company has repurchased and canceled 410,480 shares of restricted stock, and the conversion of some convertible bonds has led to an increase in registered capital from 641.700369 million yuan to 654.383263 million yuan [1][2][4]. - The total number of shares has increased from 641.700369 million to 654.383263 million [1][2]. Performance Disclosure Highlights - For the year 2024, the company reported an operating income of 9.523 billion yuan and a net profit of 1.167 billion yuan, meeting the performance assessment requirements for the third phase of the 2022 restricted stock incentive plan [2]. - The third phase of the 2022 restricted stock incentive plan has been approved for release from restrictions, involving 540 incentive targets and a total of 1,052,520 shares [2][3]. Institutional Research Highlights - The company's wholly-owned subsidiary plans to invest 70 million USD in Warburg Pincus Global Growth 15, L.P., which constitutes a related party transaction [2][4]. - The board of directors has proposed to hold the sixth extraordinary general meeting of shareholders in 2025 on November 5, 2025, to review related proposals [3].